These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1022 related articles for article (PubMed ID: 18775609)

  • 1. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
    Mueck AO
    Climacteric; 2012 Apr; 15 Suppl 1():11-7. PubMed ID: 22432811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
    L'Hermite M
    Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.
    Simon JA
    Climacteric; 2012 Apr; 15 Suppl 1():3-10. PubMed ID: 22432810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy in postmenopausal women.
    Yasui T; Uemura H; Takikawa M; Irahara M
    J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Historical perspective of hormone replacement therapy].
    Chanson P
    Rev Prat; 2005 Feb; 55(4):369-75. PubMed ID: 15828614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
    Canonico M; Oger E; Plu-Bureau G; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    Circulation; 2007 Feb; 115(7):840-5. PubMed ID: 17309934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal hormone therapy: from monkey glands to transdermal patches.
    Davis SR; Dinatale I; Rivera-Woll L; Davison S
    J Endocrinol; 2005 May; 185(2):207-22. PubMed ID: 15845914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
    van de Weijer PH; Mattsson LA; Ylikorkala O
    Maturitas; 2007 Mar; 56(3):231-48. PubMed ID: 17034966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations in the choice of oral vs. transdermal hormone therapy: a review.
    Minkin MJ
    J Reprod Med; 2004 Apr; 49(4):311-20. PubMed ID: 15134159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
    Genazzani AR; Cappagli B; Ciaponi M
    Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy in menopausal women: Past problems and future possibilities.
    Schmidt JW; Wollner D; Curcio J; Riedlinger J; Kim LS
    Gynecol Endocrinol; 2006 Oct; 22(10):564-77. PubMed ID: 17135036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
    Johansen OE; Qvigstad E
    Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A; Piette JC
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.